Scarica l'app Stockscreener
47.26
2.81%
1.29
Dopo l'orario di chiusura:
47.23
-0.03
-0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$45.97
Aprire:
$47.145
Volume 24 ore:
11.88M
Relative Volume:
0.91
Capitalizzazione di mercato:
$208.98B
Reddito:
$50.91B
Utile/perdita netta:
$18.95B
Rapporto P/E:
11.09
EPS:
4.261
Flusso di cassa netto:
$1.92B
1 W Prestazione:
+0.39%
1M Prestazione:
-4.79%
6M Prestazione:
-0.80%
1 anno Prestazione:
-3.08%
Intervallo 1D:
$46.73
$47.50
Intervallo di 1 settimana:
$43.68
$49.15
Portata 52W:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
47.26 | 219.64B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,185.71 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.24 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
246.04 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.58 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.33 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-18 | Iniziato | Bernstein | Outperform |
| 2026-03-10 | Downgrade | TD Cowen | Buy → Hold |
| 2026-03-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Downgrade | Goldman | Buy → Neutral |
| 2026-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Downgrade | Kepler | Buy → Hold |
| 2026-02-23 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Aggiornamento | Jefferies | Underperform → Hold |
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2025-12-08 | Downgrade | Argus | Buy → Hold |
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Novo Nordisk A/Sshare repurchase programme - Finansavisen
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Novo Nordisk A/S Sponsored ADR Class B Revenue Breakdown – MUN:NOVA - TradingView
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
Market news - investments.halifax.co.uk
2 Top Growth Stocks to Buy Right Now Without Any Hesitation - The Motley Fool
BR:N1VO34 Stock Latest News - TipRanks
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising - Sahm
Novo Nordisk A/S ADR (NVO-N) Stock Price and News - The Globe and Mail
Novo Nordisk (NYSE: NVO) reports 24,959,179 shares repurchased in 2026 programme - Stock Titan
Novo Nordisk's Steady Innovation in Diabetes and Obesity Have Created a Wide Moat - Morningstar
Novo Nordisk (NYSE:NVO) Wins EU Approval For Oral And Higher Dose Wegovy - Sahm
Wegovy Pill in EuropeNovo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug - Sahm
NVOH ETF Profile: Dividends, Returns (AMEX:NVOH) - TradingView
Novo Nordisk (NVO) Stock May Be 50% Undervalued Despite Medicare GLP 1 Coverage - Sahm
Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With 21% Weight Loss Data - Sahm
Total equity of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOD - TradingView
Weekly Recap: NOVO_B MAR buyback and Shares jump after UK Wegovy approval - TradingView
Novo Nordisk (NVO) Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access - Sahm
Novo Nordisk and Hims & Hers agree to partner on obesity drugs - Investing.com Nigeria
NVONovo Nordisk ADR Options - Finviz
European ADRs Slid In US Trading On Wednesday - Finimize
Novo Nordisk holds analyst rating, JPMorgan reiterates Neutral on the shares - Ad-hoc-news.de
Novo Nordisk consensus picture, shares backed by strong obesity demand - Ad-hoc-news.de
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):